Evaluation of Diagnostic Accuracy of Preoperative CT-Based Radiomics in Primary Retroperitoneal Sarcoma
- PMID: 40819146
- DOI: 10.1245/s10434-025-18040-y
Evaluation of Diagnostic Accuracy of Preoperative CT-Based Radiomics in Primary Retroperitoneal Sarcoma
Abstract
Background: Obtaining an accurate preoperative diagnosis in retroperitoneal sarcoma (RPS) is challenging, and radiomics-based models may offer a valid option to achieve this outcome. This study evaluated the accuracy of radiomics-based preoperative CT models at predicting tumour histology and grade in patients with primary RPS.
Methods: Data on consecutive patients who underwent surgery for primary retroperitoneal liposarcoma (RLPS) and leiomyosarcoma (RLMS) were analysed. Four different CT radiomics-based models were devised: 1) to distinguish between RLPS and RLMS; 2a) to predict overall tumour grade in both RLPS and RLMS; 2b and 2c) to predict tumour grade in RLPS and RMLS, respectively. The models were evaluated in a 100× random-split cross-validation.
Results: Data were available for 100 patients (64 RLPS, 36 RLMS), with 34 RLPS and 22 RLMS patients having a high-grade tumour on final histology. No significant differences in terms of age (p = 0.46), sex (p = 0.13), tumour location (p = 0.52), tumour diameter (p = 0.16), or tumour volume (p = 0.45) were observed between high- and low-grade tumours. The resulting area under the curve (AUC) at distinguishing between RLPS and RLMS was 0.94. The AUC at differentiating between high- and low-grade tumours for both RLPS and RMLS was 0.74. When tumour grade was analysed separately the corresponding AUC for RLPS and RLMS was 0.87 and 0.61, respectively.
Conclusions: Radiomics-based preoperative CT-models were demonstrated to be accurate at differentiating between RLMS and RLPS, and at predicting preoperative tumour grade in RLPS, whereas they performed poorly in RLMS.
Keywords: Leiomyosarcoma; Liposarcoma; Radiomics; Retroperitoneal sarcoma; Surgical oncology.
© 2025. Society of Surgical Oncology.
Conflict of interest statement
Disclosures: Stefan Klein—Payment to institution: EuCanImage (European Union's Horizon 2020 research and innovation program under grant agreement number 952103). Jacob Visser—Grants to institution from Promedius/Enlitic/Qure.ai; Consulting fees from Philips (payment to institution); Leadership on the steering committee of the PINPOINT Project (payment to institution from AstraZeneca). Ethical Approval: Ethical approval was obtained by the Erasmus MC medical ethics committee (MEC-2020-0293).
Similar articles
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2. Cochrane Database Syst Rev. 2018. PMID: 29357120 Free PMC article.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Radiomics Nomogram Based on Optimal Volume of Interest Derived from High-Resolution CT for Preoperative Prediction of IASLC Grading in Clinical IA Lung Adenocarcinomas: A Multi-Center, Large-Population Study.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241300734. doi: 10.1177/15330338241300734. Technol Cancer Res Treat. 2024. PMID: 39569528 Free PMC article.
References
-
- Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer. 2006;106(7):1610–6. https://doi.org/10.1002/cncr.21761 . - DOI - PubMed
-
- Morosi C, Stacchiotti S, Marchianò A, et al. Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: analysis of 291 consecutive patients at a tertiary reference sarcoma center. Eur J Surg Oncol. 2014;40:1662–70. https://doi.org/10.1016/j.ejso.2014.10.005 . - DOI - PubMed
-
- Swallow CJ, Strauss DC, Bonvalot S, et al. Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS working group. Ann Surg Oncol. 2021;28(12):7873–88. https://doi.org/10.1245/s10434-021-09654-z . - DOI - PubMed - PMC
-
- Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicenter, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366–77. https://doi.org/10.1016/S1470-2045(20)30446-0 . - DOI - PubMed
-
- Callegaro D, Raut CP, Ajayi T, et al. Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: EORTC-62092 Trial (STRASS) versus off-trial (STREXIT) results. Ann Surg. 2022 in press. https://doi.org/10.1097/SLA.0000000000005492 .
Grants and funding
LinkOut - more resources
Full Text Sources